A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01044498
First received: January 7, 2010
Last updated: March 22, 2013
Last verified: March 2013
  Purpose

This open-label, randomized, cross-over study evaluated the effect of tocilizumab (TCZ) on the pharmacokinetics and pharmacodynamics of a common oral contraceptive (OC) in female patients with active rheumatoid arthritis (RA) and in healthy female volunteers of child bearing age. The RA patients received OC in combination with TCZ, whereas the healthy volunteers received OC only. The RA patients received OC in 3 cycles of 21 days each; TCZ 8 mg/kg was administered once as an intravenous infusion on the first day of Cycle 2. The healthy volunteers received OC for only one 21-day cycle.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: Tocilizumab
Drug: Ortho-Novum® 1/35
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Serum Progesterone Level [ Time Frame: Day 21 of Cycles 1-3 for Group 1 and Day 21 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to the administration of Ortho-Novum® 1/35 on Day 21 of each cycle. Serum levels of progesterone were quantitatively determined using the ADVIA Centaur and ADVIA Centaur XP systems (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). The assay was a competitive immunoassay using direct chemiluminescent technology.


Secondary Outcome Measures:
  • Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone [ Time Frame: Day 7 of Cycles 1-3 for Group 1 and Day 7 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to and at 0.5, 1, 1.5, 2, 3, 5, 8, 12 and 24 hours after administration of Ortho-Novum® 1/35 on Day 7 of each cycle. The concentrations of ethinyl estradiol and norethindrone were determined in human heparinized plasma according to a validated gas chromatography coupled to mass spectrometry (GC-MS) method. The maximum observed plasma concentration (Cmax) was derived from the plasma concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Time to Reach the Maximum Plasma Concentration (Tmax) of Ethinyl Estradiol and Norethindrone [ Time Frame: Day 7 of Cycles 1-3 for Group 1 and Day 7 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to and at 0.5, 1, 1.5, 2, 3, 5, 8, 12 and 24 hours after administration of Ortho-Novum® 1/35 on Day 7 of each cycle. The concentrations of ethinyl estradiol and norethindrone were determined in human heparinized plasma according to a validated gas chromatography coupled to mass spectrometry (GC-MS) method. The time to reach the maximum plasma concentration (Tmax) was derived from the plasma concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Ethinyl Estradiol and Norethindrone [ Time Frame: Day 7 of Cycles 1-3 for Group 1 and Day 7 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to and at 0.5, 1, 1.5, 2, 3, 5, 8, 12 and 24 hours after administration of Ortho-Novum® 1/35 on Day 7 of each cycle. The concentrations of ethinyl estradiol and norethindrone were determined in human heparinized plasma according to a validated gas chromatography coupled to mass spectrometry (GC-MS) method. The area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) was derived from the plasma concentrations using a non-compartmental method and computed using the linear trapezoidal rule with the software WinNonlin Enterprise version 5.2 (or above).

  • Terminal Half-life (t½) of Ethinyl Estradiol and Norethindrone [ Time Frame: Day 7 of Cycles 1-3 for Group 1 and Day 7 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to and at 0.5, 1, 1.5, 2, 3, 5, 8, 12 and 24 hours after administration of Ortho-Novum® 1/35 on Day 7 of each cycle. The concentrations of ethinyl estradiol and norethindrone were determined in human heparinized plasma according to a validated gas chromatography coupled to mass spectrometry (GC-MS) method. The terminal half-life (t½) was derived from the plasma concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Apparent Oral Clearance (CL/F) of Ethinyl Estradiol and Norethindrone [ Time Frame: Day 7 of Cycles 1-3 for Group 1 and Day 7 of Cycle 1 for Group 2 ] [ Designated as safety issue: No ]
    Blood samples were collected prior to and at 0.5, 1, 1.5, 2, 3, 5, 8, 12 and 24 hours after administration of Ortho-Novum® 1/35 on Day 7 of each cycle. The concentrations of ethinyl estradiol and norethindrone were determined in human heparinized plasma according to a validated gas chromatography coupled to mass spectrometry (GC-MS) method. The apparent oral clearance (CL/F) was derived from the plasma concentrations using a non-compartmental method and computed as dose/AUC0-24 with the software WinNonlin Enterprise version 5.2 (or above).

  • Maximum Observed Serum Concentration (Cmax) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated enzyme-linked immunosorbent assay (ELISA). The maximum observed plasma concentration (Cmax) was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Time to Reach Maximum Serum Concentration (Tmax) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated ELISA. The time to reach maximum serum concentration was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Area Under the Serum Concentration-time Curve From 0 to Infinity (AUCinf) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated ELISA. The area under the serum concentration-time curve from 0 to infinity (AUCinf) was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above). AUCinf was computed using the linear trapezoidal rule to tlast plus Clast/Kel, where tlast is the time of the last measurable concentration, Clast is the last measurable concentration, and Kel is the apparent elimination rate, computed as the magnitude of the slope from the log-linear regression of the apparent terminal elimination phase of the serum concentration-versus-time curve.

  • Terminal Half-life (t½) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated ELISA. The terminal half-life (t½) was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Clearance (CL) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated ELISA. Clearance (CL), computed as dose/AUCinf, was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Apparent Volume of Distribution (Vz) of Tocilizumab [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. The concentration of tocilizumab was determined in serum samples using a validated ELISA. The apparent volume of distribution (Vz), computed as CL/Kel where CL is clearance and Kel is the apparent elimination rate, was derived from the serum concentrations using a non-compartmental method with the software WinNonlin Enterprise version 5.2 (or above).

  • Serum Soluble Interleukin-6 Receptor (sIL-6R) Level [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose and at the end of infusion of tocilizumab on Day 1 of Cycle 2. Additional blood samples were collected on Days 2, 3, 5, 7, 12, 14, and 21 of Cycle 2, and Days 1, 7, and 21 of Cycle 3. Serum levels of soluble interleukin-6 receptor were analyzed using a validated ELISA.

  • Serum C-reactive Protein (CRP) Level [ Time Frame: From Day 1 of Cycle 2 to Day 21 of Cycle 3 for Group 1 ] [ Designated as safety issue: No ]
    Blood samples were collected pre-dose of tocilizumab infusion on Day 1 of Cycle 2 and on Days 2, 3, 5, 7, 12, 14, and 21 of Cycle 2, and on Days 1, 7, and 21 of Cycle 3. Serum levels of C-reactive protein were measured by the Tina-quant CRP (latex) high-sensitivity Roche Immunoturbidimetric method.


Enrollment: 46
Study Start Date: December 2009
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)
Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
Drug: Tocilizumab
Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
Other Names:
  • RoActemra
  • Actemra
Drug: Ortho-Novum® 1/35
Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Ortho-Novum® 1/35 (Group 2)
Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
Drug: Ortho-Novum® 1/35
Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.

  Eligibility

Ages Eligible for Study:   18 Years to 44 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult patients with child bearing potential, 18-44 years of age.
  • Rheumatoid arthritis (RA) for over 6 months duration.
  • On oral contraceptive without interruption for at least 3 months with normal cycle control.
  • Treatment with disease-modifying anth-rheumatic drugs (DMARD) for at least 12 weeks prior to study start.
  • Body weight < 150 kg.

Exclusion Criteria:

  • Functional class IV rheumatoid arthritis (American College of Rheumatology [ACR] classification).
  • History of amenorrhea (unrelated to pregnancy).
  • History or current inflammatory joint disease other than RA.
  • Rheumatic autoimmune disease other than RA.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01044498

Locations
United States, Arkansas
Little Rock, Arkansas, United States, 72212
United States, California
Beverly Hills, California, United States, 90211
United States, Florida
Ormond Beach, Florida, United States, 32174
Port Orange, Florida, United States, 32127
United States, Pennsylvania
Duncansville, Pennsylvania, United States, 16635
United States, Texas
San Antonio, Texas, United States, 78222
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01044498     History of Changes
Other Study ID Numbers: NP22775
Study First Received: January 7, 2010
Results First Received: February 7, 2013
Last Updated: March 22, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Contraceptive Agents
Norinyl
Ethynylestradiol mixture with norethindrone
Norethindrone
Contraceptives, Oral
Mestranol
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptive Agents, Female
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Contraceptives, Oral, Sequential
Contraceptives, Oral, Synthetic
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on September 14, 2014